Synovial sarcoma

Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024

Details on the poster presentation are as follows:

Key Points: 
  • Details on the poster presentation are as follows:
    Session details: PO.IM01.13 - Adoptive Cell Therapies 1: Tumor Antigen-Specific T-cells and TCR-T, Sunday, April 7, 1:30 PM - 5:00 PM local time
    The work to be presented shows that recombinant T cell receptor engineered T cells (rTCR-T cells), when armored and enhanced by the PD1-41BB CSP, exhibit superior TCR-T cell functionality and safety as well as a favorable safety profile, revealing the strong potential for improving treatment of cancer patients suffering from advanced solid tumor malignancies.
  • The Company is planning a first-in-human trial for MDG1015, a TCR-T therapy incorporating the CSP in gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma with IND/CTA filing targeted for 2H 2024.
  • MDG1015 is a first-in-class, third generation TCR-T therapy targeting NY-ESO-1/ LAGE-1a, armored and enhanced by the PD1-41BB CSP.

Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors

Retrieved on: 
Monday, February 12, 2024

MDG1015 is a first-in-class, third generation TCR-T therapy targeting NY-ESO-1/ LAGE-1a, armored and enhanced by costimulatory switch protein PD1-41BB

Key Points: 
  • MDG1015 is a first-in-class, third generation TCR-T therapy targeting NY-ESO-1/ LAGE-1a, armored and enhanced by costimulatory switch protein PD1-41BB
    Planegg/Martinsried, February 12, 2024.
  • Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced the selection of gastric cancer, ovarian cancer and two types of soft tissue sarcomas, myxoid/round cell liposarcoma and synovial sarcoma, as the initial clinical indications for its lead candidate MDG1015.
  • Preclinical data presented in 2023 at the AACR and ESMO conferences demonstrated the clear potential of MDG1015 to improve clinical outcomes in solid tumors.
  • “The selection of these cancers as targets for MDG1015 is an important step as we advance towards the first-in-human trial.

Replay’s oncology-focused product company Syena and Miltenyi Biotec enter into exclusive licensing and GMP manufacturing agreement for PRAME TCR-NK cell therapy based on CliniMACS Prodigy®

Retrieved on: 
Monday, December 18, 2023

Under the terms of the agreement, Syena, the oncology-focused engineered cell therapy product company launched jointly by Replay and The University of Texas MD Anderson Cancer Center in February 2023, has secured an exclusive license to Miltenyi Biotec’s PRAME (PReferentially expressed Antigen in MElanoma) TCR.

Key Points: 
  • Under the terms of the agreement, Syena, the oncology-focused engineered cell therapy product company launched jointly by Replay and The University of Texas MD Anderson Cancer Center in February 2023, has secured an exclusive license to Miltenyi Biotec’s PRAME (PReferentially expressed Antigen in MElanoma) TCR.
  • Miltenyi Biotec will use its CliniMACS Prodigy® closed and automated cell processing platform to manufacture a scalable, GMP-compliant, PRAME-targeted, TCR-NK cell therapy product for clinical development and provision of future commercial supply.
  • The Company’s first target, NY-ESO-1, is being investigated in relapsed or refractory multiple myeloma, synovial sarcoma, and myxoid/round cell liposarcoma.
  • In line with our mission to advance cell therapies to treat patients with cancer and other serious diseases, we’re excited to collaborate with Replay and the Syena team on their GMP-compliant PRAME TCR-NK cell therapy product.”

Leiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 10, 2023

The report offers comprehensive insights into the pipeline landscape for Leiomyosarcoma, a type of cancer.

Key Points: 
  • The report offers comprehensive insights into the pipeline landscape for Leiomyosarcoma, a type of cancer.
  • It covers information about more than 10 companies and over 10 pipeline drugs related to Leiomyosarcoma.
  • Furthermore, the report offers a comprehensive overview of the current status and growth prospects within the Leiomyosarcoma pipeline landscape.
  • The assessment section of the report delves into both commercial and clinical aspects of the pipeline products in development.

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, November 1, 2023

WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today reported financial results for the third quarter ended September 30, 2023, as well as recent business highlights.

Key Points: 
  • Revenue: Total revenue for the third quarter of 2023 was $11.1 million, compared to $6.8 million for the third quarter of 2022.
  • Research and Development (R&D) Expense: R&D expense for the third quarter of 2023 was $28.3 million, compared to $29.7 million for the third quarter of 2022.
  • Net Loss and Net Loss per Share: Net loss for the third quarter of 2023 was $27.0 million, compared to $32.0 million for the third quarter of 2022.
  • Net loss per share for the third quarter of 2023 was $0.55 compared to $0.65 for the third quarter of 2022.

Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy

Retrieved on: 
Tuesday, October 24, 2023

IMA203 is a TCR-T cell therapy targeting PRAME, a protein frequently expressed in a large variety of solid tumors.

Key Points: 
  • IMA203 is a TCR-T cell therapy targeting PRAME, a protein frequently expressed in a large variety of solid tumors.
  • “The FDA RMAT designation for multiple indications underscores the broad potential of IMA203 and the benefits it may provide for advanced-stage solid tumor patients.
  • This is an important regulatory milestone and a recognition of our clinical development progress for this program,” said Cedrik Britten, Chief Medical Officer of Immatics.
  • As of Sep 30, 2023, the U.S. FDA has received at least 238 requests for RMAT designations and granted 922.

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myelom

Retrieved on: 
Wednesday, October 11, 2023

WATERTOWN, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced plans to share data from the Phase 1 dose escalation portions of the ongoing Phase 1/2 trials of CFT7455 and CFT8634. The CFT8634 Phase 1 dose escalation data has been accepted as a poster presentation at the Connective Tissue Oncology Society (CTOS) Annual Meeting taking place from November 1 – 4, 2023 in Dublin, Ireland. C4T will host a company-sponsored event on December 12, 2023, to share the CFT7455 dose escalation data in relapsed/refractory multiple myeloma (R/R MM).

Key Points: 
  • C4T will host a company-sponsored event on December 12, 2023, to share the CFT7455 dose escalation data in relapsed/refractory multiple myeloma (R/R MM).
  • As of August 29, 2023, 32 patients were enrolled across six dose escalation cohorts using a daily dosing schedule.
  • Enrollment continues for the Phase 1 dose escalation evaluating CFT7455 with dexamethasone in R/R MM and as a monotherapy in R/R NHL.
  • November 14, 2023: Management will participate in the Stifel 2023 Conference taking place in New York, NY.

Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

Retrieved on: 
Wednesday, October 4, 2023

The conference will be held October 11–15, 2023, in Boston, Massachusetts.

Key Points: 
  • The conference will be held October 11–15, 2023, in Boston, Massachusetts.
  • Foghorn will highlight data from its FHD-286 program demonstrating its potential as a broad-based hematologic and solid tumor differentiation agent, including clinical data in acute myeloid leukemia (AML), metastatic uveal melanoma (mUM), and pre-clinical data in non-small cell lung cancer (NSCLC) and prostate cancer.
  • Also at AACR-NCI-EORTC, the Company will present data from its selective EP300 program, including in vitro selective degradation and antiproliferation in AR+ prostate and DLBCL cell lines.
  • The EP300 program targets CBP mutant cancers and subsets of EP300 dependent malignancies, which include bladder, NSCLC, and various leukemias and lymphomas.

Immatics Announces Second Quarter 2023 Financial Results and Business Update

Retrieved on: 
Thursday, August 17, 2023

“Beyond our recent IMA203 updates, we are pleased to report that we closed the second quarter with a cash position funding operations into late 2025.

Key Points: 
  • “Beyond our recent IMA203 updates, we are pleased to report that we closed the second quarter with a cash position funding operations into late 2025.
  • As per the latest data cut-off of April 4, 2023, ACTengine® IMA203 TCR-T monotherapy Cohort A showed a 67% confirmed objective response rate (cORR) in an interim clinical update announced on May 2, 2023.
  • Next update on Immatics’ IMA203 Phase 1b cohorts, including the projected clinical development path for PRAME-targeted TCR-T monotherapy towards registration-directed trials is planned for 4Q 2023.
  • TCER® IMA402 (PRAME) – Immatics submitted a clinical trial application (CTA2) to the Paul-Ehrlich-Institute (PEI) in April 2023.

Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors

Retrieved on: 
Thursday, August 10, 2023

IMA402 is the second product candidate in Immatics’ TCER® pipeline of next-generation, half-life extended bispecific molecules to enter clinical development.

Key Points: 
  • IMA402 is the second product candidate in Immatics’ TCER® pipeline of next-generation, half-life extended bispecific molecules to enter clinical development.
  • It targets an HLA-A*02:01-presented peptide derived from PRAME, a clinically established cancer target frequently expressed in a large variety of solid tumors.
  • The Phase 1/2 clinical trial ( NCT 05958121 ) investigates TCER® IMA402 in HLA-A*02:01-positive patients with PRAME-expressing recurrent and/or refractory solid tumors.
  • Immatics has implemented an adaptive design for the dose escalation with the goal of accelerating the clinical development timeline of IMA402.